UNCY Unicycive Therapeutics Inc
$4.82
$0.01
(0.21%)
Pre-Market
37
Bearish Sentiment
How do you feel about UNCY?
Ad free · Full sentiment data · Expanded watchers · Advanced search · No credit card required.
Advertisement|
UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class Action - Contact SueWallSt
UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class Action - Contact SueWallSt UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class Action - Contact SueWallStPR NewswireNEW...
PR Newswire
UNCY Investor Alert: Unicycive Therapeutics, Inc. Securities Class Action Notice - Contact Levi & Korsinsky
UNCY Investor Alert: Unicycive Therapeutics, Inc. Securities Class Action Notice - Contact Levi & Korsinsky UNCY Investor Alert: Unicycive Therapeutics, Inc. Securities Class Action Notice - Contact Levi & KorsinskyPR NewswireNEW YORK, Sept. 23, 2026 A securities class action alleges Unicycive...
PR Newswire
Robbins LLP Urges UNCY Stockholders Who Lost Money Investing in Unicycive Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action
Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Unicycive Therapeutics, Inc. (NASDAQ: UNCY) securities between December 29, 2025 and June 29, 2026. Unicycive is a clinical-stage...
Business Wire
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud LawsuitPR NewswireNEW YORK, Sept. 18, 2026 NEW YORK, Sept. 18, 2026 /PRNewswire/ --Rosen Law Firm, a global investor...
PR Newswire
UNCY Shareholder Alert: Unicycive Therapeutics, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt
UNCY Shareholder Alert: Unicycive Therapeutics, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt UNCY Shareholder Alert: Unicycive Therapeutics, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallStPR NewswireNEW YORK, Sept. 17, 2026 A securities class...
PR Newswire
UNCY DEADLINE: Levi & Korsinsky Reminds Unicycive Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline
UNCY DEADLINE: Levi & Korsinsky Reminds Unicycive Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline UNCY DEADLINE: Levi & Korsinsky Reminds Unicycive Therapeutics, Inc. Investors of Upcoming Securities Class Action DeadlinePR NewswireNEW YORK, Sept. 16, 2026 A securities...
PR Newswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY ROSEN, SKILLED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in...
PR Newswire
Levi & Korsinsky Reminds Unicycive Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 2, 2026 - UNCY
Levi & Korsinsky, LLP notifies institutional investors in Unicycive Therapeutics, Inc. (NASDAQ: UNCY) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between December 29, 2025 and June 29, 2026. Request an institutional investor loss assessment. You may...
Business Wire
UNCY INVESTOR REMINDER: Unicycive Therapeutics, Inc. Investors Have Until November 2, 2026 To Contact Kirby McInerney LLP to Seek Lead Plaintiff Role
If you have suffered a loss on your Unicycive Therapeutics, Inc. (Unicycive or the Company) (NASDAQ: UNCY) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud...
Business Wire